Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: Results from quantitative computed tomography-based finite element analysis of the vertebral body

Bone

Volumn 46, Issue 1, 2010, Pages 41-48

  Chevalier, Yan ^a   Quek, Evelyn ^b   Borah, Babul ^c   Gross, Gary ^c   Stewart, John ^d   Lang, Thomas ^b   Zysset, Philippe ^a  

^a VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d SANOFI   (France)

Author keywords

Bisphosphonate; Finite element analysis; Osteoporosis; Teriparatide; Vertebra

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE[1-34]; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE; PROTEIN PRECURSOR; RISEDRONIC ACID; UNCLASSIFIED DRUG;

ABSORPTIOMETRY; ADULT; AGED; ARTICLE; BONE DENSITY; BONE STRENGTH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FINITE ELEMENT ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; QUANTITATIVE ANALYSIS; TRABECULAR BONE; TREATMENT DURATION; VERTEBRA BODY;

AGED; ALENDRONATE; BIOMECHANICS; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; FINITE ELEMENT ANALYSIS; HUMANS; MIDDLE AGED; OSTEOPOROSIS; TERIPARATIDE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 72049085513     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.09.032     Document Type: Article

References (30)

1. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis (2008), Washington, DC, National Osteoporosis Foundation
2. Ettinger B., San Martin J., Crans G., and Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Miner. Res. 19 (2004) 745-751
3. Miller P.D., Delmas P.D., Lindsay R., Watts N.B., Luckey M., Adachi J., et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J. Clin. Endocrinol. Metab. 93 (2008) 3785-3793
4. Graeff C., Chevalier Y., Charlebois M., Varga P., Pahr D., Nickelsen T.N., et al. Improvements in vertebral body strength under teriparatide Treatment assessed in vivo by finite element : Results from the EUROFORS study. J Bone Miner Res 24 (2009) 1672-1680
5. Imai K., Ohnishi I., Matsumoto T., Yamamoto S., and Nakamura K. Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Osteoporos. Int. 20 (2009) 801-810
6. Imai K., Ohnishi I., Yamamoto S., and Nakamura K. In vivo assessment of lumbar vertebral strength in elderly women using computed tomography-based nonlinear finite element model. Spine 33 (2008) 27-32
7. Keaveny T.M., Donley D.W., Hoffmann P.F., Mitlak B.H., Glass E.V., and San Martin J.A. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J. Bone Miner. Res. 22 (2007) 149-157
8. Lang T.F., Keyak J.H., Heitz M.W., Augat P., Lu Y., Mathur A., et al. Volumetric quantitative computed tomography of the proximal femur: precision and relation to bone strength. Bone 21 (1997) 101-108
9. Lang T.F., Li J., Harris S.T., and Genant H.K. Assessment of vertebral bone mineral density using volumetric quantitative CT. J. Comput. Assist. Tomogr. 23 (1999) 130-137
10. Chevalier Y., Charlebois M., Pahr D., Varga P., Heini P., Schneider E., et al. A patient-specific finite element methodology to predict damage accumulation in vertebral bodies under axial compression, sagittal flexion and combined loads. Comput. Methods Biomech. Biomed. Engin. 11 (2008) 477-487
11. Garcia D., Zysset P., Charlebois M., and Curnier A. A three-dimensional elastic plastic damage constitutive law for bone tissue. Biomech. Model. Mechanobiol. 8 (2009) 149-165
12. Parfitt A.M. Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone 13 Suppl. 2 (1992) S41-47
13. Seeman E., and Delmas P.D. Bone quality - the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354 (2006) 2250-2261
14. Riggs B.L., and Melton III L.J. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J. Bone Miner. Res. 17 (2002) 11-14
15. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349 (2003) 1207-1215
16. Russell R.G., Watts N.B., Ebetino F.H., and Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19 (2008) 733-759
17. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interaction with hydroxyapatite. Bone 38 (2006) 617-627
18. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., et al. Effects of continuing or stopping of alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296 (2006) 2927-2938
19. Watts N.B., Chines A., Olszynski W.P., McKeever C.D., McClung M.R., Zhou X., et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos. Int. 19 (2008) 365-372
20. Chevalier Y., Pahr D., and Zysset P.K. The role of cortical shell and trabecular Fabric in Finite Element analysis of the human vertebral body. J Biomech Eng 131 11 (2009) 111003 10.1115/1.3212097
21. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J. Clin. Invest. 92 (1993) 2577-2586
22. Burr D.B., Hirano T., Turner C.H., Hotchkiss C., Brommage R., and Hock J.M. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J. Bone Miner. Res. 16 (2001) 157-165
23. Roschger P., Paschalis E.P., Fratzl P., and Klaushofer K. Bone mineralization density distribution in health and disease. Bone 42 (2008) 456-466
24. Wang X., Allen M.R., Burr D.B., Lavernia E.J., Jeremić B., and Fyhrie D.P. Identification of material parameters based on Mohr-Coulomb failure criterion for bisphosphonate treated canine vertebral cancellous bone. Bone 43 (2008) 775-780
25. Hernandez C.J., Beaupré G.S., Keller T.S., and Carter D.R. The influence of bone volume fraction and ash fraction on bone strength and modulus. Bone 29 (2001) 74-78
26. Eastell R., Cedel S.L., Wahner H.W., Riggs B.L., and Melton III L.J. Classification of vertebral fractures. J. Bone Miner. Res. 6 (1991) 207-215
27. Crawford R.P., and Keaveny T.M. Relationship between axial and bending behaviors of the human thoracolumbar vertebra. Spine 29 (2004) 2248-2255
28. Boonen S., Fernando M., et al. Effects of prior antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 92 (2007) 1415-1423
29. Dobnig H., Sipos A., et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J. Clin. Endocrinol. Metab. 90 (2005) 3970-3977
30. Chen P., Satterwhite J.H., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 20 (2005) 962-970